基于基因的N-乙转移酶代谢多态性和低水平的环境暴露于致癌物质
P Vineis1, H Bartsch, N Caporaso
1Dipartimento di Scienze Biomediche e Oncologia Umana, University and Main Hospital, Torino, Italy.
Nature
|May 12, 1994
概括
遗传变异会影响身体如何处理致癌物质. 缓慢的乙化剂,一个遗传组,在低环境暴露时显示出更高的致癌性添加物,影响风险评估.
科学领域:
- 环境健康 环境健康
- 毒理学 毒理学 毒理学
- 人类遗传学 人类遗传学
背景情况:
- 致癌物代谢在个体之间有很大的差异,受遗传因素的影响.
- 对致癌物质的个体间敏感性至关重要,特别是在低环境暴露水平时.
- 环境烟草烟雾和柴油废气是广泛暴露低剂量的人类致癌物质的例子.
研究的目的:
- 为了研究N-乙化表型/基因型和人类的致癌素添加剂水平之间的关系.
- 评估遗传因素如何调节与低剂量环境致癌物暴露相关的风险.
主要方法:
- 量化了膀细胞中的DNA添加物和97名志愿者的4-aminobiphenyl-hemoglobin添加物.
- 确定N-乙化非诱导性表型,相应的基因型,以及尿中的尼古丁-可丁因水平.
- 与乙化状态和暴露标志物相关联的引物水平.
主要成果:
- 缓慢的乙化剂表现出高于快速的乙化剂在低或零的尼古丁-丁水平的4-氨基双添加剂.
- 缓慢和快速乙化剂之间的 adduct 水平的差异随着尼古丁-cotinine 水平的增加而减少.
- N-乙转移酶基因型强烈预测了乙化表型.
结论:
- 遗传倾向,特别是缓慢化剂表型,会损害低剂量致癌物的清除.
- 低剂量环境风险的基因调制是"风险评估"程序的关键考虑因素.
- 了解个体遗传差异对于准确的环境风险评估至关重要.
相关概念视频
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Spontaneous and Induced Mutations
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).


